More on NAMS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $29.64 |
|
|||
| Open | $29.64 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $29.64 | ||||
| Day Low | $29.64 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,495 | ||||
- EU panel backs NewAmsterdam and Menarini cholesterol drugs
- NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co
- Form 4 NewAmsterdam Pharma Co For: Jul 20 Filed by: Kooij Louise Frederika
- BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform
- Jefferies Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
- Attovia Therapeutics names John Smither to board of directors
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
- NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
Entities mentioned with NAMS
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- F1 | View Related Stories »
- Show More...
